Dissecting the effects of androgen deprivation therapy on cadherin switching in advanced prostate cancer: A molecular perspective

Basit Öğe Kaydı
dc.authorid0000-0002-4337-9327en_US
dc.authorid0000-0003-0172-6957en_US
dc.contributor.authorVarışli, Lokman
dc.contributor.authorTolan, Veysel
dc.contributor.authorCen, Jiyan H.
dc.contributor.authorVlahopoulas, Spiros
dc.contributor.authorCen, Osman
dc.date.accessioned2023-01-20T11:56:14Z
dc.date.available2023-01-20T11:56:14Z
dc.date.issued2022en_US
dc.departmentDicle Üniversitesi, Fen Fakültesi, Moleküler Biyoloji ve Genetik Bölümüen_US
dc.description.abstractProstate cancer is one of the most often diagnosed malignancies in males and its prevalence is rising in both developed and developing countries. Androgen deprivation therapy has been used as a standard treatment approach for advanced prostate cancer for more than 80 years. The primary aim of androgen deprivation therapy is to decrease circulatory androgen and block androgen signaling. Although a partly remediation is accomplished at the beginning of treatment, some cell populations become refractory to androgen deprivation therapy and continue to metastasize. Recent evidences suggest that androgen deprivation therapy may cause cadherin switching, from E-cadherin to N-cadherin, which is the hallmark of epithelial-mesenchymal transition. Diverse direct and indirect mechanisms are involved in this switching and consequently, the cadherin pool changes from E-cadherin to N-cadherin in the epithelial cells. Since E-cadherin represses invasive and migrative behaviors of the tumor cells, the loss of E-cadherin disrupts epithelial tissue structure leading to the release of tumor cells into surrounding tissues and circulation. In this study, we review the androgen deprivation therapy-dependent cadherin switching in advanced prostate cancer with emphasis on its molecular basis especially the transcriptional factors regulated through TFG-β pathway.en_US
dc.identifier.citationVarışli, L., Tolan, V., Cen, J.H., Vlahopoulas, S. ve Cen, O. (2022). Dissecting the effects of androgen deprivation therapy on cadherin switching in advanced prostate cancer: A molecular perspective. Oncology Research, 30(3), 137-155.en_US
dc.identifier.doi10.32604/or.2022.026074
dc.identifier.endpage155en_US
dc.identifier.issue3en_US
dc.identifier.pmid37305018
dc.identifier.scopus2-s2.0-85156153129
dc.identifier.scopusqualityQ2
dc.identifier.startpage137en_US
dc.identifier.urihttps://www.techscience.com/or/v30n3/51285
dc.identifier.urihttps://hdl.handle.net/11468/11212
dc.identifier.volume30en_US
dc.identifier.wosWOS:000918221200004
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorVarışli, Lokman
dc.institutionauthorTolan, Veysel
dc.language.isoenen_US
dc.publisherTech Science Pressen_US
dc.relation.ispartofOncology Research
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectProstate canceren_US
dc.subjectAndrogen signalingen_US
dc.subjectAndrogen deprivation therapyen_US
dc.subjectCadherin switchingen_US
dc.titleDissecting the effects of androgen deprivation therapy on cadherin switching in advanced prostate cancer: A molecular perspectiveen_US
dc.titleDissecting the effects of androgen deprivation therapy on cadherin switching in advanced prostate cancer: A molecular perspective
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Makale.pdf
Boyut:
1.75 MB
Biçim:
Adobe Portable Document Format
Açıklama:
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Moleküler Biyoloji ve Genetik Bölümü Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu